Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Prostate Cancer Prostatic DisJun 20, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Quoc-Dien Trinh, Daniel J George, Neal Shore et al.

✦ AI-curated · Sources linked

In 30 seconds

The ARANOTE phase 3 trial analyzed the efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) specifically in Black patients with metastatic hormone-sensitive prostate cancer. Among 65 Black patients, darolutamide combined with ADT significantly improved radiological progression-free survival (rPFS), reducing the risk of radiological progression or death by 49% compared to ADT alone.

Key findings

  • Darolutamide plus ADT reduced the risk of radiological progression or death by 49% compared to ADT alone.
  • The study included 65 Black patients, representing 10% of the total ARANOTE population.
  • Patients received darolutamide 600 mg twice daily or placebo in a 2:1 randomization.

Why it matters

This study highlights the potential benefits of darolutamide in improving treatment outcomes for Black patients with metastatic hormone-sensitive prostate cancer, a population that may experience disparities in care.

Source

PubMed · PMID 42323390Free full text on PubMed Central

Published in Prostate Cancer Prostatic Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.